Metformin prescription patterns among US adolescents aged 10–19 years: 2009–2013
Open accessAbstract
WHAT IS KNOWN AND OBJECTIVE: Metformin is the only oral antihyperglycemic agent approved for use in adolescents with type 2 diabetes mellitus (T2DM). There are reports of metformin used to treat conditions such as obesity, hyperinsulinemia, prediabetes, metabolic syndrome and polycystic ovarian syndrome (PCOS). It is important to understand metformin prescription patterns and underlying diagnoses in adolescents as it can provide estimates of the extent of on-label (i.e. treatment of T2DM) and off-label use of metformin in this population. Our study sought to assess metformin prescription patterns among US adolescents from 2009 to 2013. METHODS: Data from the National Disease and Therapeutic Index (NDTI) database, the MarketScan(®) Commercial Claims and Encounters database and the Multi-State Medicaid database were analysed. The proportion of diagnoses associated with metformin that was recommended during a clinical visit was identified in the NDTI database. In the MarketScan(®) Commercial and Medicaid databases, adolescents with at least one metformin prescription with ±6 months continuous enrolment from the date of the index metformin prescription were included in the analyses. All diagnosis and procedure codes were extracted within ±6 months of the index metformin prescription. The proportion of T2DM was calculated irrespective of any other medical conditions, whereas all other prespecified conditions were classified as positive only if no concurrent T2DM diagnosis codes were present. RESULTS AND DISCUSSION: In the NDTI database, the most common diagnoses associated with metformin use were diabetes (34·9%), followed by metabolic syndrome (20·9%), PCOS (17·2%) and obesity (6·5%). In the MarketScan(®) Commercial database, T2DM was the most common diagnosis among girls aged 10-14 years (22·8-23·6%), boys aged 10-14 years (20·5-24·5%) and boys aged 15-19 years (37·1-43·1%), whereas PCOS (24·1-28·3%) was the most common diagnosis among girls aged 15-19 years. In the Medicaid database, T2DM was the most common diagnosis among all four groups and the proportions were higher than their counterparts in the Commercial database. WHAT IS NEW AND CONCLUSION: Analyses from three separate US data sources suggest that off-label prescribing of metformin is common among US adolescents aged 10-19 years. To avoid potential overestimation, caution should be exercised when utilizing metformin prescription as a proxy measure to estimate the burden of T2DM in adolescents.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
It is commonly used in adolescents 15 to 19 years of age despite being "off label" for this indication.
“It is commonly used in adolescents 15 to 19 years of age despite being “off label” for this indication [177].”
From Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls (2019) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072 · see citing works
Prevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents From 2001 to 2009
Dabelea, D., Mayer-Davis, E. J., Saydah, S., Imperatore, G., Linder, B., Divers, J., Bell, R., Badaru, A., Talton, J. W., Crume, T., et al. (2014) · JAMA · doi:10.1001/jama.2014.3201 · Cited by 1,412 · see citing works
Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-29 · Cited by 1,309 · see citing works
McGuire, S. (2014) · Advances in Nutrition · doi:10.3945/an.114.007211 · Cited by 1,122 · see citing works
Incidence of diabetes in youth in the United States
SEARCH for Diabetes in Youth Study Group*, T. W. G. F. T. (2007) · JAMA · doi:10.1001/jama.297.24.2716 · Cited by 991 · see citing works
Type 2 diabetes in children and adolescents. American Diabetes Association.
(2000) · Diabetes Care · doi:10.2337/diacare.23.3.381 · Cited by 936 · see citing works
Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2050
Imperatore, G., Boyle, J. P., Thompson, T. J., Case, D., Dabelea, D., Hamman, R. F., Lawrence, J. M., Liese, A. D., Liu, L. L., Mayer‐Davis, E. J., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0669 · Cited by 485 · see citing works
Prevalence of Diabetes in U.S. Youth in 2009: The SEARCH for Diabetes in Youth Study
Pettitt, D. J., Talton, J. W., Dabelea, D., Divers, J., Imperatore, G., Lawrence, J. M., Liese, A. D., Linder, B. L., Mayer‐Davis, E. J., Pihoker, C., et al. (2013) · Diabetes Care · doi:10.2337/dc13-1838 · Cited by 428 · see citing works
Type 2 diabetes in children and adolescents
Rosenbloom, A. L., Silverstein, J. H., Amemiya, S., Zeitler, P. S., & KLINGENSMITH, G. J. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00584.x · Cited by 147 · see citing works
Unlicensed use of metformin in children and adolescents in the UK
Hsia, Y., Dawoud, D., Sutcliffe, A. G., Viner, R., Kinra, S., & Wong, I. C. K. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04063.x · Cited by 44 · see citing works
Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands
FARSANI, S. F. F., Souverein, P. C., Overbeek, J. A., van der Vorst, M. M. J., Knibbe, C. A. J., Herings, R. M. C., de Boer, A., & Mantel-Teeuwisse, A. K. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12608 · Cited by 9 · see citing works
Unlicensed use of metformin in children and adolescents in Germany and France
Kostev, K., & Richter, H. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04099.x · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00078 · Cited by 653 · see citing works
Ibáñez, L., Oberfield, S. E., Witchel, S., Auchus, R. J., Chang, R. J., Codner, E., Dabadghao, P., Darendeliler, F., Elbarbary, N. S., Gambineri, A., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000479371 · Cited by 463 · see citing works
Anticancer Activity of Metformin: A Systematic Review of the Literature
Aljofan, M., & Riethmacher, D. (2019) · Future Science OA · doi:10.2144/fsoa-2019-0053 · Cited by 160 · see citing works
Olatunde, A., Nigam, M., SINGH, R. K., Panwar, A. S., Lasisi, A., Alhumaydhi, F. A., Kumar, V., Mishra, A. P., & Sharifi‐Rad, J. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02202-5 · Cited by 93 · see citing works
Suaya, J. A., Gessner, B. D., Fung, S. M., Vuocolo, S. C., Scaife, J., Swerdlow, D. L., Istúriz, R., & Arguedas, A. G. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.10.060 · Cited by 83 · see citing works
Emerging Trends in Metformin Prescribing in the United States from 2000 to 2015
Le, S., & Lee, G. C. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00799-0 · Cited by 42 · see citing works
Yen, H., Chang, Y.-T., Yee, F.-J., & Huang, Y. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00565-5 · Cited by 27 · see citing works
Update on off label use of metformin for obesity
El‐Arabey, A. A. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.02.004 · Cited by 22 · see citing works
Organic cation transporters 2: Structure, regulation, functions, and clinical implications
Ailabouni, A. S., & Prasad, B. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100044 · Cited by 17 · see citing works
Progression from prediabetes to type 2 diabetes mellitus in adolescents: a real world experience
Weiner, A., Zhang, M., Ren, S., Tchang, B. G., Gandica, R., & Murillo, J. E. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1181729 · Cited by 17 · see citing works
Dokras, A., Coutifaris, C., Remaley, A. T., Mehta, N. N., Playford, M. P., Kunselman, A. R., Stetter, C. C., Dodson, W. C., & Legro, R. S. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004662 · Cited by 7 · see citing works
Polycystic ovary syndrome in pediatric obesity and diabetes
DONDI, E., TUFANO, M., VIGONE, M. C., LUCACCIONI, L., POZZOBON, G., Ubertini, G., MOZZILLO, E., & Delvecchio, M. (2021) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06542-3 · Cited by 5 · see citing works
Swauger, S. E., & Crimmins, N. A. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.184 · Cited by 4 · see citing works
El‐Arabey, A. A., Abdalla, M., Abd‐Allah, A. R. A., Marenga, H. S., Modafer, Y., & Aloufi, A. S. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103699 · Cited by 4 · see citing works
Polycystic ovary syndrome in adolescence: Toward a better diagnosis and treatment
Evans, A. T., & Hoeger, K. M. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.04.010 · Cited by 4 · see citing works
Jensen, H. K., Rasmussen, L., Furu, K., Karlstad, Ø., Linder, M., Cesta, C. E., & Pottegård, A. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14867 · Cited by 4 · see citing works
Disparities in the Diagnosis and Management of Polycystic Ovarian Syndrome in Adolescents
Waldrop, S., Buenaventura, M., Reyes, K. J. C., & Stanford, F. C. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2025.02.016 · Cited by 3 · see citing works
Managing PCOS in the Adolescent
Burgert, T. S., & Paprocki, E. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_10
Fahad, N. S., Ali, I. N., & Aiad, N. W. (2023) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2023.300788
Dokras, A., Coutifaris, C., Remaley, A. T., Mehta, N. N., Playford, M. P., Kunselman, A. R., Stetter, C. M., William, D., & Legro, R. S. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5236696
Peter‐Marske, K. M., Zhang, X., Wang, T., Liu, X., Fernandes, G. F., Engel, S. S., & Shankar, R. R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334971
Godoy, J. A., Ríos, J. A., de Mayo, T., Henriquez, J. F., Abello, C. S. M., Avendaño, M. E., Villanueva, M. G., Chávez, F. S., & Garrido, M. (2026) · Discover Oncology · doi:10.1007/s12672-026-04760-4
Interindividual variability in metformin pharmacokinetics in pediatric patients
Ailabouni, A. S., Halpin, K. L., Boone, E. C., Gaedigk, A., Nadai, T., Irie, K., Mizuno, T., Leeder, J. S., & Prasad, B. (2026) · Pediatric Research · doi:10.1038/s41390-026-04938-0
- Authors
- Wang, T., McNeill, A. M., Chen, Y., Senderak, M., & Shankar, R. R.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Wang, T.
- ORCID
- Shankar, R. R.
- Venue
- Journal of Clinical Pharmacy and Therapeutics
- Publisher
- Hindawi Limited
- Published
- 2016-03-09
- Volume
- 41
- Issue
- 2
- Pages
- 229-236
- ISSN
- 0269-4727 (ISSN-L)
- OpenAlex
- W2295180243
- Cited by
- 24
- References
- 12
- Citations by year
- 2026: 2 · 2025: 6 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 1
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Pharmacy and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- metformin, prescribing patterns, adolescents, type 2 diabetes, off-label drug use, polycystic ovary syndrome, metabolic syndrome, obesity, hyperinsulinemia, prediabetes, Medicaid, commercial insurance claims
- MeSH terms
- Adolescent, Adult, Child, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Metformin, Practice Patterns, Physicians', Drug Prescriptions, United States, Databases, Factual, Young Adult, Off-Label Use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
